DUX4 and facioscapulohumeral muscular dystrophy: Unlike therapies that exclusively target DUX4—the primary genetic culprit in FSHD—hemichannel-targeting strategies hold the potential to be effective in both FSHD1 and FSHD2, as they address mechanisms that are not solely dependent on DUX4 expression.